Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8N4G2
UPID:
ARL14_HUMAN
Alternative names:
ADP-ribosylation factor 7
Alternative UPACC:
Q8N4G2; Q9H655
Background:
ADP-ribosylation factor-like protein 14, also known as ADP-ribosylation factor 7, plays a pivotal role in the immune response by regulating the movement of MHC class II-containing vesicles in dendritic cells. This is achieved through its GTPase activity, which recruits MYO1E to these vesicles via the effector protein ARL14EP, facilitating their transport along the actin cytoskeleton.
Therapeutic significance:
Understanding the role of ADP-ribosylation factor-like protein 14 could open doors to potential therapeutic strategies.